#stankostrong…” On April 29, 2024, Jonathan Stanko received a diagnosis of stage four Adenocarcinoma gastric cancer. On May 10, 2024, he shared his journey in a blog post. Jonathan Stanko ...

The G/GEJ adenocarcinoma market is forecast to be worth $4.72bn in 2029. "BeiGene’s Tevimbra approved in US for first-line gastric cancer treatment" was originally created and published by ...

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

Concordance between PD-L1 assays 28-8 and SP263 and their respective scoring algorithms in procured upper gastrointestinal adenocarcinoma samples. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Aspirin reduced recurrence by 50% in PIK3CA-mutated colorectal cancer, the DCISionRT test earned FDA breakthrough status for predicting radiotherapy benefit in DCIS, and nivolumab plus chemotherapy ...

Recognising the pressing need for new therapies, the FDA has already granted a fast-track designation to zolbetuximab for the treatment of gastric and GEJ adenocarcinoma. Other companies ...

Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including colorectal and prostate cancers.

Role of intraperitoneal paclitaxel in eosinophil activation and recruitment in the peritoneal cavity and anti-tumor effects against peritoneal metastasis from gastric cancer. This is an ASCO Meeting ...